New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
05:30 EDTABBVAbbVie invests $320M in Singapore
AbbVie Inc. announces a $320M investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally. The investment will establish the first manufacturing presence in Asia by AbbVie. Other AbbVie operations in Asia include research and development functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie's existing presence in Singapore includes 120 personnel, supporting commercial operations, global R&D and general operations.
News For ABBV From The Last 14 Days
Check below for free stories on ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
09:22 EDTABBVAbbVie initiates Phase III clinical trial of veliparib in lung cancer
AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib or ABT-888, in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer. The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo. The trial will recruit approximately 900 patients.
April 14, 2014
17:31 EDTABBVAbbVie stock could reach $55, Barron's says
Subscribe for More Information
07:45 EDTABBVAbbVie defended at BMO Capital
Subscribe for More Information
April 12, 2014
19:23 EDTABBVEnanta reports detailed results from Turquoise ll study
Enanta Pharmaceuticals (ENTA) announced that detailed results from AbbVie’s (ABBV) pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation at the International Liver Congress, ILC, which is the 49th Annual Meeting of the European Association for the Study of the Liver, EASL. Results from the TURQUOISE-II study were featured in the ILC press conference and were published on-line in the New England Journal of Medicine. The TURQUOISE-II study reports results from AbbVie’s investigational three direct-acting antiviral regimen containing ABT-450, Enanta’s lead protease inhibitor discovered through Enanta’s collaboration with AbbVie. The regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's three direct-acting antiviral regimen with ribavirin, RBV, in adult patients with genotype 1, GT1, chronic hepatitis C virus, HCV, infection with compensated liver cirrhosis. Patients achieved sustained virologic response rates 12 weeks post-treatment, SVR12, of 91.8% and 95.9% in the 12-week and 24-week treatment arms, respectively. Patients in the study were either new to therapy or treatment-experienced, failed previous treatment with pegylated interferon and RBV.
April 11, 2014
05:27 EDTABBVEnanta announces results for partner AbbVie's HCV studies
Subscribe for More Information
05:24 EDTABBVAbbVie announces 96% sustained virologic response rates in HCV study
Subscribe for More Information
April 9, 2014
11:43 EDTABBVGilead defended by analysts after recent pullback
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use